Oct 20, 2021
- Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent
- GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent
- Global COVID-19 testing-related sales were $1.9 billion in the third quarter
- Excluding COVID-19 testing-related sales, third-quarter sales grew 11.7 percent on both a reported and organic basis compared to sales in 2019
- Continues to strengthen portfolio with several new product approvals